Based on the regression coefficients and gene expression levels, we constructed a clinical prognosis assessment system for PAAD patients with RiskScore = 0.128 * APOL1 + 0.153 * BHLHE40 − 0.552 * CLMP − 0.363 * GNG12 + 0.528 * LOX − 0.202 * LY6E − 0.202 * MYL12B + 0.051 * RND3 + 1.003 * SOX4. This evidence concerns the gene LY6E and pancreatic adenocarcinoma.